Dinutuximab Beta Recommended for Refractory and Relapsed High-Risk Neuroblastoma

We’re delighted to announce that the Medical Services Advisory Committee (MSAC) is officially recommending Dinutuximab beta (Qarziba®) in combination with chemotherapy for the treatment of primary relapsed or refractory high-risk neuroblastoma.